Avanza Fonder Ab Alkermes Plc. Transaction History
Avanza Fonder Ab
- $3.86 Trillion
- Q3 2025
A detailed history of Avanza Fonder Ab transactions in Alkermes Plc. stock. As of the latest transaction made, Avanza Fonder Ab holds 8,220 shares of ALKS stock, worth $238,708. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,220
Previous 8,136
1.03%
Holding current value
$238,708
Previous $233 Million
5.94%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
400Shares Held
176MCall Options Held
901KPut Options Held
400K-
Black Rock Inc. New York, NY29.1MShares$845 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$528 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.2MShares$297 Million0.03% of portfolio
-
State Street Corp Boston, MA8.54MShares$248 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY8.09MShares$235 Million1.98% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.77B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...